SK284971B6 - Použitie estrogénu na výrobu lieku na liečenie fyzických stavov spôsobených poklesom estrogénu u subjektu po prechode a kit obsahujúci estrogén - Google Patents

Použitie estrogénu na výrobu lieku na liečenie fyzických stavov spôsobených poklesom estrogénu u subjektu po prechode a kit obsahujúci estrogén Download PDF

Info

Publication number
SK284971B6
SK284971B6 SK733-2000A SK7332000A SK284971B6 SK 284971 B6 SK284971 B6 SK 284971B6 SK 7332000 A SK7332000 A SK 7332000A SK 284971 B6 SK284971 B6 SK 284971B6
Authority
SK
Slovakia
Prior art keywords
estrogen
estradiol
women
levels
administered
Prior art date
Application number
SK733-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK7332000A3 (en
Inventor
Steven Cummings
Herman Ellman
Bruce Ettinger
Original Assignee
The Regents Of The University Of California
Kaiser Foundation Health Plan, Inc.
The Permanente Medical Group, Inc.
Berlex Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25523181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK284971(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Regents Of The University Of California, Kaiser Foundation Health Plan, Inc., The Permanente Medical Group, Inc., Berlex Laboratories, Inc. filed Critical The Regents Of The University Of California
Publication of SK7332000A3 publication Critical patent/SK7332000A3/sk
Publication of SK284971B6 publication Critical patent/SK284971B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
SK733-2000A 1997-11-21 1998-11-19 Použitie estrogénu na výrobu lieku na liečenie fyzických stavov spôsobených poklesom estrogénu u subjektu po prechode a kit obsahujúci estrogén SK284971B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/975,599 US5891868A (en) 1997-11-21 1997-11-21 Methods for treating postmenopausal women using ultra-low doses of estrogen
PCT/US1998/024677 WO1999026631A1 (en) 1997-11-21 1998-11-19 Methods for treating postmenopausal women using ultra-low doses of estrogen

Publications (2)

Publication Number Publication Date
SK7332000A3 SK7332000A3 (en) 2001-03-12
SK284971B6 true SK284971B6 (sk) 2006-03-02

Family

ID=25523181

Family Applications (1)

Application Number Title Priority Date Filing Date
SK733-2000A SK284971B6 (sk) 1997-11-21 1998-11-19 Použitie estrogénu na výrobu lieku na liečenie fyzických stavov spôsobených poklesom estrogénu u subjektu po prechode a kit obsahujúci estrogén

Country Status (26)

Country Link
US (1) US5891868A (pt)
EP (2) EP1032398B1 (pt)
JP (2) JP2001523722A (pt)
KR (1) KR100576568B1 (pt)
CN (1) CN100398110C (pt)
AT (2) ATE291430T1 (pt)
AU (1) AU760108B2 (pt)
BR (1) BR9814984A (pt)
CA (1) CA2306881C (pt)
CL (1) CL2004001852A1 (pt)
CZ (1) CZ299226B6 (pt)
DE (2) DE69839026T2 (pt)
EA (1) EA004573B1 (pt)
EE (1) EE04221B1 (pt)
ES (2) ES2299912T3 (pt)
HK (1) HK1082919A1 (pt)
HU (1) HUP0004339A3 (pt)
IL (1) IL136175A (pt)
IS (1) IS2132B (pt)
NO (1) NO326929B1 (pt)
NZ (1) NZ504668A (pt)
PL (1) PL193897B1 (pt)
PT (1) PT1032398E (pt)
SK (1) SK284971B6 (pt)
TR (1) TR200001460T2 (pt)
WO (1) WO1999026631A1 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US5891868A (en) * 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen
US6692763B1 (en) * 1998-11-19 2004-02-17 The Regents Of The University Of California Methods for treating postmenopausal women using ultra-low doses of estrogen
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
CN1404394A (zh) * 2000-01-14 2003-03-19 斯特里克斯有限公司 组合物
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20030092686A1 (en) * 2000-10-13 2003-05-15 Amdahl Michael J. Method of determining the initial dose of vitamin D compounds
CA2448235A1 (en) 2001-07-31 2003-02-13 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
WO2005011617A2 (en) * 2003-07-31 2005-02-10 Ivax Corporation Transmucosal dosage forms for brain-targeted steroid chemical delivery systems
US7685012B2 (en) * 2003-12-30 2010-03-23 Wilson Thomas W Method and system for analyzing resource allocation based on cohort times
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
EP1853272A1 (en) * 2005-02-03 2007-11-14 Duramed Pharmaceuticals, Inc. Compositions of unconjugated estrogens and methods for their use
US8834862B2 (en) * 2005-04-19 2014-09-16 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
JP2009521533A (ja) * 2005-12-27 2009-06-04 デュラメド ファーマシューティカルズ インコーポレーティッド 結合型エストロゲン組成物、アプリケーター、キット、ならびにそれらの作製および使用の方法
US20070254036A1 (en) * 2006-04-13 2007-11-01 Besins Healthcare Sa Treatment of menopause associated symptoms
KR101583680B1 (ko) * 2007-10-15 2016-01-08 알자 코퍼레이션 펜타닐의 1일-1회 교체 경피 투여
US20090110656A1 (en) * 2007-10-31 2009-04-30 Lemke Sarah A Skin cooling composition
US20090157153A1 (en) * 2007-12-13 2009-06-18 Sarah Anne Lemke Skin cooling system
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
CA2796139A1 (en) * 2010-04-15 2011-10-20 Bayer Intellectual Property Gmbh Low-dosed solid oral dosage forms for hrt
HUP1000335A2 (en) * 2010-06-22 2012-02-28 Avidin Kft Use of an estrogen derivative for the treatment and/or prevention of psychiatric conditions
RU2456955C1 (ru) * 2011-03-01 2012-07-27 Государственное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ ортопедического лечения женщин постменопаузального периода съемными пластиночными протезами
CN102397550B (zh) * 2011-08-30 2013-05-08 广东医学院 一组由阿司匹林与雌激素组成的防治骨质疏松症的药物组合物
JP2013097693A (ja) * 2011-11-04 2013-05-20 Hitachi Solutions Ltd 骨粗鬆症リスク判定システム及びプログラム
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP3054934B1 (en) * 2013-10-07 2024-05-22 Teikoku Pharma USA, Inc. Methods and compositions for treating withdrawal syndromes using non-sedative dexmedetomidine transdermal compositions
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US5188835A (en) * 1986-06-16 1993-02-23 Kabi Pharmacia Ab Intravaginal devices
SE8602666D0 (sv) * 1986-06-16 1986-06-16 Leo Ab Intravaginal devices
US5223261A (en) * 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
JP2960832B2 (ja) * 1992-05-08 1999-10-12 ペルマテック テクノロジー アクチェンゲゼルシャフト エストラジオールの投与システム
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
US5891868A (en) * 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen

Also Published As

Publication number Publication date
DE69839026D1 (de) 2008-03-06
EA004573B1 (ru) 2004-06-24
IS5468A (is) 2000-04-26
HUP0004339A3 (en) 2001-09-28
EP1032398A1 (en) 2000-09-06
HK1082919A1 (en) 2006-06-23
AU1591499A (en) 1999-06-15
DE69839026T2 (de) 2009-01-08
EP1570848A1 (en) 2005-09-07
WO1999026631A1 (en) 1999-06-03
PL193897B1 (pl) 2007-03-30
JP2004083599A (ja) 2004-03-18
AU760108B2 (en) 2003-05-08
CZ299226B6 (cs) 2008-05-21
DE69829501D1 (de) 2005-04-28
DE69829501T2 (de) 2006-01-26
KR20010032257A (ko) 2001-04-16
EP1570848B1 (en) 2008-01-16
ES2241188T3 (es) 2005-10-16
NO20002587L (no) 2000-07-19
EE200000307A (et) 2001-10-15
CA2306881A1 (en) 1999-06-03
ES2299912T3 (es) 2008-06-01
IL136175A0 (en) 2001-05-20
BR9814984A (pt) 2000-10-03
SK7332000A3 (en) 2001-03-12
PT1032398E (pt) 2005-08-31
KR100576568B1 (ko) 2006-05-08
EA200000563A1 (ru) 2001-08-27
ATE383862T1 (de) 2008-02-15
ATE291430T1 (de) 2005-04-15
EE04221B1 (et) 2004-02-16
EP1032398B1 (en) 2005-03-23
CN1279611A (zh) 2001-01-10
PL341112A1 (en) 2001-03-26
IL136175A (en) 2005-11-20
JP2001523722A (ja) 2001-11-27
TR200001460T2 (tr) 2000-11-21
IS2132B (is) 2006-08-15
CL2004001852A1 (es) 2005-06-03
NZ504668A (en) 2002-11-26
CA2306881C (en) 2008-09-02
US5891868A (en) 1999-04-06
NO326929B1 (no) 2009-03-16
NO20002587D0 (no) 2000-05-19
HUP0004339A2 (hu) 2001-05-28
CZ20001602A3 (cs) 2001-02-14
CN100398110C (zh) 2008-07-02

Similar Documents

Publication Publication Date Title
SK284971B6 (sk) Použitie estrogénu na výrobu lieku na liečenie fyzických stavov spôsobených poklesom estrogénu u subjektu po prechode a kit obsahujúci estrogén
US6692763B1 (en) Methods for treating postmenopausal women using ultra-low doses of estrogen
JP5184727B2 (ja) 女性への非経口アンドロゲンステロイドの投与
Field et al. Preventive effects of transdermal 17β-estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial
Cooper et al. Matrix delivery transdermal 17β-estradiol for the prevention of bone loss in postmenopausal women
Prelevic et al. Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women
Cunningham et al. Plasma sex hormone-binding globulin and androgen levels in the management of hirsute patients
Perrotti et al. Forearm bone density in long-term users of oral combined contraceptives and depot medroxyprogesterone acetate
Cobb et al. Oral contraceptives and bone mineral density in white and black women in CARDIA
Castelo-Branco et al. Effects on bone mass of two oral contraceptives containing ethinyl-estradiol and cyproterone acetate or desogestrel: results of a 2-year follow-up
Ginsburg et al. Polycystic ovary syndrome.
Whitehead et al. Effects in Postmenopausal Women of Natural and Synthetic Estrogens on Calcitonin and Calcium‐Regulating Hormone Secretion: Relevance to Postmenopausal Osteoporosis
Crilly et al. The vitamin D metabolites in the pathogenesis and management of osteoporosis
Shoupe Androgens and bone: clinical implications for menopausal women
Bayley et al. The long‐term treatment of steroid osteoporosis with fluoride
Guichard et al. Comparison of the Pharmacokinetics of 17β‐Estradiol after a Single 4‐Day Application of Oesclim® 50, Oesclim® 100, and Vivelle® 0.05 (Menorest® 50) Transdermal Delivery Systems
MXPA00004924A (es) El uso de dosis ultra-bajas de estrógeno para preparar un medicamento para el tratamiento de mujeres post-menopáusicas
Siegberg et al. Endocrine and clinical effects of spironolactone in female hyperandrogenism
Minkoff et al. Interactions of medroxyprogesterone acetate with estrogen on the calcium-parathyroid axis in post-menopausal women
Carr et al. Effect of gonadotropin-releasing hormone agonist and medroxyprogesterone acetate on calcium metabolism: a prospective, randomized, double-blind, placebo-controlled, crossover trial
Nishibe et al. Comparison of effects of estriol on bone mineral density of vertebrae between elderly and postmenopausal women
US20220313705A1 (en) Cyproterone acetate compositions and uses thereof
Adler Preventing and Treating Glucocorticoid Osteoporosis

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20151119